NICE rejection of Erbitux in head and neck cancer is final
This article was originally published in Scrip
Executive Summary
Using Merck Serono's (Merck KGaA) Erbitux (cetuximab), in combination with platinum-based chemotherapy, to treat patients in England and Wales with recurrent and/or metastatic squamous cell cancer of the head and neck would not be a cost-effective use of UK national health service resources, an assessment agency has found.